Rapid Labs Ltd

Rapid Labs Ltd specialises in diagnostic tools for blood typing and immunoassay testing. Their products include automated Automatic Chemiluminescence Immunoassay Analyzers, which automate laboratory testing for efficiency, as well as Cup Readers for manual sample analysis. Additionally, they produce monoclonal antibodies—such as Anti-A, Anti-B, and Anti-D (IgG & IgM)—used to detect specific blood group antigens in laboratory settings. These devices are designed to support accurate and reliable diagnostic workflows.

Rapid Labs Ltd is based in the United Kingdom, which means its devices are subject to EU regulatory frameworks (e.g., IVDR) if marketed in the European Economic Area. Since their products are listed in eudamed, they comply with EU requirements for In Vitro Diagnostic (IVD) devices. The UK’s alignment with EU regulations ensures their devices meet necessary standards for safety, performance, and traceability in the EU market.

Rapid Labs Ltd’s devices are listed in the eudamed database, the official EU registry for In Vitro Diagnostic (IVD) medical devices. This registration is critical because it demonstrates compliance with EU requirements, facilitates transparency for healthcare providers and regulators, and ensures traceability of devices under the IVDR (In Vitro Diagnostic Regulation). Listing in eudamed is mandatory for IVD manufacturers seeking to legally market their products in the EU.

Rapid Labs Ltd’s devices fall under Class A (low-risk) and IVD Annex II List A classifications. Class A devices are generally considered low-risk, requiring basic conformity assessments, while Annex II List A includes devices like blood grouping reagents that pose minimal risk but still require validation for accuracy and safety. This classification ensures users can rely on their performance for critical diagnostic tasks, such as blood typing, while maintaining streamlined regulatory oversight.